Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,041.7
-29.5 (-0.96%)

 

  • STI Straits Times Index
    3,041.7
    -29.5 (-0.96%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,527.9
    -20.6 (-1.33%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    24,099.1
    -821.6 (-3.30%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,614.0
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    30,323.3
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,076.3
    -56.9 (-0.93%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,423.4M
  • Value: 1,459.2M
  • Rise: 78
  • Fall: 304
  • Unch: 373

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.065-0.008
Sembcorp Marine0.082-0.002
Medi Lifestyle0.033-0.001
Singtel2.440+0.010
CapLand IntCom T2.000-
YZJ Shipbldg SGD1.440-0.040
Intl Cement0.031-0.002
Jiutian Chemical0.077-0.005
VCPlus0.027+0.001
CapitaLandInvest2.950-

World Indices

World Indices
Name Last Change
Nasdaq 14,713.9 -330.1
HSI 24,099.1
HSCEI 8,638.5
Jakarta 6,076.3
Nikkei 225 30,500.0
SSE Comp 3,614.0
Shanghai A 3,787.7
Shanghai B 273.1
KOSPI 3,130.1

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NOVARTIS AG SPONSORED ADR
Updated on 17 Sep 2021 (End of trading day)
Last (USD): 83.480 Change: -0.900 High: 84.080 Remarks: -
Change (%): -1.07 Low: 83.030
Open 83.900 Yesterday's Close 84.38000000000001
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 2,036,604 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 3.33557 Trailing EPS (USD) e 3.69457 NAV (USD) b 22.1991
PE a 25.027 Trailing PE f 22.595 Price / NAV b 3.7605
Dividend (USD) d 1.927702 Cash In Hand (USD) g 2.1019 Issued & Paid-up Shares c 2,434,420,000
Dividend Yield (%) d 2.309 Price / Cash In Hand g 39.716 Treasury Shares h 239,453,391
Market Cap (M) 203,225.382 Enterprise Value (M) 233,800.344
Piotroski F Score 6 Exchange Code NVS Par Value ( $ ) n.a.
52 Weeks Volatility (%) 20.82 Free Float (%) -
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 15 Jul 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 17 Sep 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 203,225.382 25.027 22.595 3.7605 2.309
Industry Pharmaceuticals: Major NYSE 115,834.876 33.033 27.726 5.4441 2.817
Local Peer JOHNSON & JOHNSON NYSE 433,701.080 29.475 24.410 6.2331 2.416
Local Peer PFIZER INC NYSE 246,077.624 25.590 18.603 3.5133 3.461
Local Peer ELI LILLY AND COMPANY NYSE 220,109.288 35.538 36.258 34.1552 1.286
Local Peer ABBVIE INC NYSE 190,378.301 41.786 28.893 15.1466 4.488
Local Peer MERCK & CO INC NYSE 181,448.602 25.675 32.570 5.4499 3.458
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 179,755.310 27.896 25.250 17.1931 1.327
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 136,237.564 - - 3.7013 3.031
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 97,942.819 13.285 16.513 4.6107 5.315
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 54,271.346 15.308 13.439 1.1499 4.468
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 8,829.162 - - -19.4527 -
Local Peer ORGANON & CO NYSE 8,628.136 3.995 3.995 -4.4613 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 3,068.458 10.057 10.256 1.9877 -
Other Local Peers ADC THERAPEUTICS SA (NYSE), ZYMEWORKS INC (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 172,139.326 53.861 45.648 10.9811 2.089
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 122,252.873 8.709 17.654 1.6302 2.764
Global Peer WUXI APPTEC HKEx 534,219.675 160.960 115.360 12.1010 0.195
Global Peer ROYALTY PHARMA PLC NASDAQ 23,376.122 23.975 24.061 4.0770 0.498
Global Peer REPLIGEN CORP NASDAQ 16,872.503 281.554 168.838 10.5251 -
Global Peer VIATRIS INC NASDAQ 16,410.065 - - 0.7738 -
Global Peer HANSOH PHARMA HKEx 119,039.235 41.238 38.524 5.2913 0.383
Global Peer INNOVENT BIO HKEx 100,276.000 - - 7.0080 -
Global Peer CANSINOBIO-B HKEx 92,388.060 - 117.307 10.9558 -
Global Peer CUREVAC NV NASDAQ 10,262.584 - - - -
Other Global Peers ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HUTCHMED (HKEx), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), ALLAKOS INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), SH PHARMA (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), JUNSHI BIO (HKEx), CMS (HKEx), HYGEIA HEALTH (HKEx), AKESO-B (HKEx), BAIYUNSHAN PH (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), INNOCARE-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), CARSGEN-B (HKEx), CHINARES PHARMA (HKEx), NEKTAR THERAPEUTICS (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), OPKO HEALTH INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), EVEREST MED-B (HKEx), SIMCERE PHARMA (HKEx), IGM BIOSCIENCES INC (NASDAQ), ERASCA INC (NASDAQ), TRAD CHI MED (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), CSTONE PHARMA-B (HKEx), HENLIUS (HKEx), SSY GROUP (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), OCUMENSION-B (HKEx), HEPALINK (HKEx), NURIX THERAPEUTICS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), GENERATION BIO CO (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), KRONOS BIO INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ICOSAVAX INC (NASDAQ), UNITED LAB (HKEx), FULCRUM THERAPEUTICS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), TONGRENTANGCM (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH-B (HKEx), PHATHOM PHARMACEUTICALS INC (NASDAQ), ANTENGENE-B (HKEx), KINNATE BIOPHARMA INC (NASDAQ), GH RESEARCH PLC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), SCICLONE PHARMA (HKEx), ORIC PHARMACEUTICALS INC (NASDAQ), Kimia Farma Tbk. (IDX), CKLIFE SCIENCES (HKEx), SUTRO BIOPHARMA INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), BEYONDSPRING INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ANNEXON INC (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), SHINEWAY PHARM (HKEx), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), PETIQ INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), HUA MEDICINE-B (HKEx), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), ZHAOKE OPHTH-B (HKEx), SIGA TECHNOLOGIES INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), EVOLUS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), 89BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), PROVENTION BIO INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), IGBB (Bursa), CLEARSIDE BIOMEDICAL INC (NASDAQ), ESSA PHARMA INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), RACE ONCOLOGY LTD (ASX), APPLIED THERAPEUTICS INC (NASDAQ), NEXIMMUNE INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CYBIN INC (NYSE American), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), TOT BIOPHARM-B (HKEx), DAWNRAYS PHARMA (HKEx), CITIUS PHARMACEUTICALS INC (NASDAQ), DURECT CORP (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), XOMA CORP (NASDAQ), OBSEVA SA (NASDAQ), BSTEAD (Bursa), INOZYME PHARMA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), ANNOVIS BIO INC (NYSE American), MUSTANG BIO INC (NASDAQ), PHARMA (Bursa), VECTIVBIO HLDG AG (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), FUSEN PHARM (HKEx), HARROW HEALTH INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), KALEIDO BIOSCIENCES INC (NASDAQ), IMMUNIC INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), ALZAMEND NEURO INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), TRICIDA INC (NASDAQ), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), IP (SET), RENEO PHARMACEUTICALS INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CH BIOTECH SER (HKEx), TYME TECHNOLOGIES INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NOVAN INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), GENPREX INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ZHONGZHIPHARM (HKEx), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), IX Biopharma (SGX), RECCE PHARMACEUTICALS LTD (ASX), EYENOVIA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), IMARA INC (NASDAQ), Merck Tbk. (IDX), LYRA THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), KOTRA (Bursa), CHARMACY PHAR (HKEx), MEDIWOUND LTD (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), NEW RAY MEDIC (HKEx), MOLECULIN BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), GRAYBUG VISION INC (NASDAQ), Phapros Tbk. (IDX), SANAI HEALTH GP (HKEx), PAK FAH YEOW (HKEx), ABVC BIOPHARMA INC (NASDAQ), NC HEALTHCARE (HKEx), VIRPAX PHARMA INC (NASDAQ), NOVA (Bursa), Hyphens Pharma (SGX), INVION LTD (ASX), BIOHLDG (Bursa), BRICKELL BIOTECH INC (NASDAQ), RENOVORX INC (NASDAQ), MANNATECH INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), MODERN CHI MED (HKEx), EXOPHARM LTD (ASX), NEP INTERLONG (HKEx), INHIBIKASE THERAPEUTICS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), UNIVERSE PHARMACEUTICALS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), VALLON PHARMACEUTICALS INC (NASDAQ), WAI YUEN TONG (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), SEQLL INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), PURAPHARM (HKEx), AGEX THERAPEUTICS INC (NYSE American), TELIGENT INC NEW (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), DERMATA THERAPEUTICS INC (NASDAQ), EXTRAWELL PHAR (HKEx), PAINREFORM LTD (NASDAQ), PALLA PHARMA LTD (ASX), JCT (SET), NLS PHARMACEUTICS LTD (NASDAQ), SUNZEN (Bursa), HOTH THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ACRUX (ASX), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), SINOLIFE UTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --1.780
-2.09 %
10 Days --7.920
-8.67 %
20 Days --10.270
-10.95 %
Medium Term Return 3 Months --10.430
-11.11 %
6 Months --3.030
-3.50 %
1 Year --6.020
-6.73 %
Long Term Return 2 Years --3.130
-3.61 %
3 Years 2.834+8.603
+15.27 %
5 Years 8.488+12.606
+29.76 %
Annualised Return Annualised --
+5.35 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 77.040 - 98.520 Change From 1 Year Low +6.440 % Change From 1 Year Low (%) +8.36
Change From 1 Year High -15.040 % Change From 1 Year High (%) -15.27
2 Years Range 69.180 - 99.843 Change From 2 Years Low +14.300 % Change From 2 Years Low (%) +20.67
Change From 2 Years High -16.363 % Change From 2 Years High (%) -16.39
5 Years Range 58.758 - 99.843 Change From 5 Years Low +24.721 % Change From 5 Years Low (%) +42.07
Change From 5 Years High -16.363 % Change From 5 Years High (%) -16.39
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Historical Price Data

Date Open High Low Close Volume VWAP
17 Sep 2021 83.900 84.080 83.030 83.480 2,036,604 -
16 Sep 2021 84.680 84.850 84.035 84.380 1,852,188 -
15 Sep 2021 85.160 85.350 84.800 85.080 1,557,978 -
14 Sep 2021 85.720 85.860 85.225 85.280 1,426,413 -
13 Sep 2021 85.730 85.730 85.010 85.260 1,486,487 -
10 Sep 2021 86.130 86.300 85.380 85.430 1,551,745 -
09 Sep 2021 87.290 87.340 86.460 86.490 2,116,451 -
08 Sep 2021 87.950 88.080 87.550 87.570 1,882,576 -
07 Sep 2021 90.310 90.490 89.440 89.440 1,115,745 -
03 Sep 2021 91.590 91.700 90.890 91.400 1,743,789 -
02 Sep 2021 92.230 92.380 91.650 92.150 2,020,584 -
01 Sep 2021 92.650 92.970 92.390 92.650 2,304,814 -
31 Aug 2021 93.000 93.650 92.155 92.390 2,892,662 -
30 Aug 2021 91.430 91.860 91.400 91.650 1,554,340 -
27 Aug 2021 91.810 92.340 91.600 92.020 1,847,425 -
26 Aug 2021 91.530 91.770 91.380 91.560 2,008,999 -
25 Aug 2021 91.570 91.955 91.180 91.830 2,815,505 -
24 Aug 2021 93.120 93.120 92.130 92.150 2,845,869 -
23 Aug 2021 93.860 94.250 93.540 93.750 996,532 -
20 Aug 2021 92.680 93.490 92.470 93.330 2,206,062 -
19 Aug 2021 92.935 93.470 92.735 93.200 4,285,660 -
18 Aug 2021 94.730 94.780 93.430 93.440 1,961,397 -
Summary
Current 2 Weeks
(03 Sep 2021 to 17 Sep 2021)
91.590 91.700 83.030 83.480 16,769,976 -
Previous 2 Weeks
(20 Aug 2021 to 02 Sep 2021)
92.680 93.490 83.030 92.150 21,492,792 -
4 Weeks from
(23 Jul 2021 to 19 Aug 2021)
91.860 92.060 83.030 93.200 34,391,488 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.